COVID-19

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.cdc.gov/coronavirus/

Get the latest research information from NIH: https://www.covid19.nih.gov

Pinkal Desai

I am a Cancer Epidemiologist and Physician Scientist/Researcher.

Pinkal Desai, M.D.

Weill Cornell Medical College

As a physician treating hematologic malignancies, I personally saw the devastating impact of hematologic cancers in my patients, and many patients would ask me how they could have prevented these cancers. The literature was severely lacking in this field, and this motivated me to combine my skills as a cancer epidemiologist and clinician to study early detection and prevention strategies for hematologic malignancies.

Dr. Desai is a cancer epidemiologist and hematologist at Weill Cornell Medicine (WCM), NY. Her clinical research is focused on treating patients with hematologic malignancies, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In addition, she is an epidemiologist with a strong research interest in the epidemiology of hematological malignancies, particularly in studying preventative strategies in hematological malignancies. Hematologic malignancies are a major cause of morbidity and mortality with no known prevention strategies. Her experience with patients drove her into the field of early detection and prevention. Her prior work in the field of early detection of pre-leukemic clones in population databases established for the first time a premalignant state in AML. She leads a multidisciplinary team of investigators as the Clinical Director of Molecular Aging Initiative at the Englander Institute of Precision Medicine at WCM, with a focus on clonal hematopoiesis and aging.

Dr. Desai's current NCI-funded research project is focused on identifying pre-disease mutations and risk factors for progression to hematologic malignancies. This work will lead to an early detection and monitoring strategy for patients at risk for hematologic malignancies. Successful completion of this work will lead to creation of preventative strategies for MDS, AML, and other hematologic malignancies.


Grant Listing
Project Title Grant Number Program Director Publication(s)
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
1R01CA248747-01A1
Charlisse Caga-anan


To request edits to this profile, please contact Mark Alexander at alexandm@mail.nih.gov.

Last Updated: 05/12/2021 01:04:46